QBiotics Announces First Patient Dosed in its Phase I/II Clinical Trial of Tigilanol Tiglate for Head and Neck Cancer

  • First patient successfully dosed in QBiotics' Phase I/II clinical trial of tigilanol tiglate in patients with Head and Neck Squamous Cell Carcinoma (HNSCC)
  • Tigilanol tiglate is a novel, small molecule that is being tested as a single injection treatment for solid tumours......
    . .
    Veröffentlicht von: Finanzen.at - Nachrichten Ticker - 5 days ago
Share |